Zacks: DermTech (NASDAQ:DMTK) Receives Consensus Rating of “Strong Buy” from Analysts
Shares of DermTech (NASDAQ:DMTK) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Zacks has also given DermTech an industry rank of 60 out of 254 based on the ratings given to related companies.
Separately, Lake Street Capital reaffirmed a “buy” rating and issued a $24.00 target price on shares of DermTech in a research report on Friday, May 1st.
Institutional investors have recently added to or reduced their stakes in the stock. Casdin Capital LLC bought a new position in shares of DermTech in the 1st quarter valued at about $5,642,000. Victory Capital Management Inc. grew its position in shares of DermTech by 25.3% in the 1st quarter. Victory Capital Management Inc. now owns 385,397 shares of the company’s stock valued at $4,336,000 after acquiring an additional 77,704 shares during the period. Perceptive Advisors LLC bought a new position in shares of DermTech in the 1st quarter valued at about $3,215,000. Maven Securities LTD bought a new position in shares of DermTech in the 1st quarter valued at about $2,418,000. Finally, Federated Hermes Inc. bought a new position in shares of DermTech in the 1st quarter valued at about $810,000. 39.14% of the stock is owned by institutional investors and hedge funds.
Shares of DMTK stock traded down $0.26 during trading hours on Monday, hitting $13.48. 50,700 shares of the company were exchanged, compared to its average volume of 50,960. The company has a 50 day moving average of $12.61. DermTech has a 52 week low of $4.52 and a 52 week high of $23.24.
DermTech (NASDAQ:DMTK) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.07). The firm had revenue of $1.56 million for the quarter.
DermTech, Inc, a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.
Featured Article: Moving Average – How it Helps Investors in Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.